Biogen Alzheimer's Drug Impresses

WSJ.com: US Business, Wall Street Journal: Business
Fri, 03/20/2015 - 10:46am

A Biogen Idec drug that targets plaque buildup in the brain slowed cognitive decline in some Alzheimer’s patients in an early-stage study.

NEXT
Topics:  biogen idec   alzheimer s   drug   
BING NEWS:
  • Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
    Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's also unlikely to appease broader investor concerns.
    01/13/2025 - 4:42 am | View Link
  • Sage Therapeutics shares spike after Biogen offers to buy remaining stake
    Investing.com - Shares in Sage Therapeutics (NASDAQ: SAGE) were more than 36% higher in premarket US trading on Monday, fueled by news that drugmaker Biogen (NASDAQ: BIIB) has proposed to buy all ...
    01/12/2025 - 10:50 pm | View Link
  • Patrizia Cavazzoni, head of FDA’s drug center, to leave the agency
    Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
    01/10/2025 - 3:54 am | View Link
  • Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity
    Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.
    01/9/2025 - 4:00 pm | View Link
  • Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
    The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...
    01/9/2025 - 4:36 am | View Link
  • More
BING SEARCH:
  • Biogen discontinues Alzheimer’s medication Aduhelm
    The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the...
    01/11/2025 - 6:31 pm | View Website
  • Biogen to Realign Resources for Alzheimer's Disease Franchise
    CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
    01/11/2025 - 2:18 am | View Website
  • Biogen’s Decision to Discontinue Alzheimer’s Drug | alz.org
    CHICAGO, Jan. 31, 2024 — Despite today’s announcement from Biogen, the Alzheimer’s Association is extremely optimistic about the future of Alzheimer’s treatments; a new era that started with the Food and Drug Administration (FDA) accelerated approval of Aduhelm in 2021.
    01/10/2025 - 9:03 pm | View Website
  • Biogen to cease production of controversial Alzheimer’s drug
    Drugmaker Biogen will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment that also provoked controversy over conflicting data around its efficacy, the...
    01/9/2025 - 3:13 pm | View Website
  • Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for ...
    In the large trial of lecanemab, which is given by infusion, the drug slowed the rate of cognitive decline in patients with early Alzheimer's by 27% compared to a placebo.
    01/9/2025 - 8:47 am | View Website
  • More
NEXT
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

Movies With Butter More Movie News

More Business News